Vol 52, No 2 (2021)
Short communication
Published online: 2021-04-29

open access

Page views 370
Article views/downloads 508
Get Citation

Connect on Social Media

Connect on Social Media

Myelodysplasia-associated Sweet’s syndrome: clinical and laboratory presentation and response to thalidomide

Bartlomiej Wawrzycki1, Dariusz Jawniak2, Aldona Pietrzak1, Justyna Szumilo3, Dorota Krasowska1
Acta Haematol Pol 2021;52(2):132-136.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Vignon-Pennamen MD. Sweet's syndrome. In: Wallach D, Vignon-Pennamen MD, Valerio Marzano A. ed. Neutrophilic dermatoses. Springer International Publishing, Cham 2018: 13–35.
  2. Nelson CA, Stephen S, Ashchyan HJ, et al. Neutrophilic dermatoses: pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J Am Acad Dermatol. 2018; 79(6): 987–1006.
  3. Lepelletier C, Bouaziz JD, Rybojad M, et al. Neutrophilic dermatoses associated with myeloid malignancies. Am J Clin Dermatol. 2019; 20(3): 325–333.
  4. Hoffbrand AV, Vyas P, Campo E, Haferlach T, Gomez K. Color atlas of clinical hematology. Wiley Blackwell, Hoboken 2018: 256–270.
  5. Van Loon K, Gill RM, McMahon P, et al. 20q- clonality in a case of oral sweet syndrome and myelodysplasia. Am J Clin Pathol. 2012; 137(2): 310–315.
  6. Nelson CA, Noe MH, McMahon CM, et al. Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol. 2018; 78(2): 303–309.e4.
  7. Kulasekararaj AG, Kordasti S, Basu T, et al. Chronic relapsing remitting Sweet syndrome — a harbinger of myelodysplastic syndrome. Br J Haematol. 2015; 170(5): 649–656.
  8. Vignon-Pennamen MD, Juillard C, Rybojad M, et al. Chronic recurrent lymphocytic Sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases. Arch Dermatol. 2006; 142(9): 1170–1176.
  9. Kakaletsis N, Kaiafa G, Savopoulos C, et al. Initially lymphocytic Sweet's syndrome in male patients with myelodysplasia: a distinguished clinicopathological entity? Case report and systematic review of the literature. Acta Haematol. 2014; 132(2): 220–225.
  10. Mekinian A, Grignano E, Braun T, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016; 55(2): 291–300.
  11. Navarini AA, Satoh TK, French LE. Neutrophilic dermatoses and autoinflammatory diseases with skin involvement — innate immune disorders. Semin Immunopathol. 2016; 38(1): 45–56.
  12. Fenini G, Contassot E, French LE. Potential of IL-1, IL-18 and inflammasome inhibition for the treatment of inflammatory skin diseases. Front Pharmacol. 2017; 8: 278.
  13. Wallach D, Vignon-Pennamen MD. Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses. Br J Dermatol. 2018; 178(3): 595–602.
  14. Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018; 132(15): 1553–1560.
  15. Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019; 133(10): 1039–1048.
  16. Heath MS, Ortega-Loayza AG. Insights into the pathogenesis of Sweet's syndrome. Front Immunol. 2019; 10: 414.
  17. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010; 24(1): 22–32.
  18. Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol. 2008; 27(3): 111–135.
  19. Keller M, Sollberger G, Beer HD. Thalidomide inhibits activation of caspase-1. J Immunol. 2009; 183(9): 5593–5599.
  20. Lee C, Do HT, Her J, et al. Inflammasome as a promising therapeutic target for cancer. Life Sci. 2019; 231: 116593.
  21. Lee DJ, Li H, Ochoa MT, et al. Integrated pathways for neutrophil recruitment and inflammation in leprosy. J Infect Dis. 2010; 201(4): 558–569.
  22. Yasui K, Kobayashi N, Yamazaki T, et al. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr Pharm Des. 2005; 11(3): 395–401.
  23. Lauridsen HM, Pellowe AS, Ramanathan A, et al. Tumor necrosis factor-α and IL-17A activation induces pericyte-mediated basement membrane remodeling in human neutrophilic dermatoses. Am J Pathol. 2017; 187(8): 1893–1906.
  24. Browning CE, Dixon JE, Malone JC, et al. Thalidomide in the treatment of recalcitrant Sweet's syndrome associated with myelodysplasia. J Am Acad Dermatol. 2005; 53(2 Suppl 1): S135–S138.
  25. Fozza C, La Nasa G, Caocci G. The Yin and Yang of myelodysplastic syndromes and autoimmunity: the paradox of autoimmune disorders responding to therapies specific for MDS. Crit Rev Oncol Hematol. 2019; 142: 51–57.
  26. Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014; 15(11): e493–e503.
  27. Bastuji-Garin S, Ochonisky S, Bouche P, et al. Thalidomide Neuropathy Study Group. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002; 119(5): 1020–1026.
  28. Tamburini J, Elie C, Park S, et al. Groupe Francophone des Myélodysplasies, GFM. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leuk Res. 2009; 33(4): 547–550.